Loading...
•
Sep 30, 2021
Ocugen Q3 2021 Earnings Report
Ocugen reported third quarter 2021 financial results with focus on advancing COVAXIN and ophthalmic pipeline.
Key Takeaways
Ocugen reported a net loss of $10.755 million, or $0.05 per share, for the third quarter of 2021. The company's cash, cash equivalents, and restricted cash totaled $107.5 million as of September 30, 2021. Ocugen filed an EUA for COVAXIN for children aged 2-18 years and two IND applications with the FDA.
Filed Emergency Use Authorization (EUA) application with the U.S. FDA for COVAXIN™ for children aged 2 – 18 years.
Filed Investigational New Drug (IND) application with the U.S. FDA for COVAXIN™.
Filed Investigational New Drug (IND) application with the U.S. FDA for breakthrough modifier gene therapy candidate, OCU400.
Expanded collaboration with CanSinoBIO to include OCU410 for chemistry, manufacturing, and controls development and manufacturing.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...